This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 29/11/1802    most recent ATVBAHA.109.194688v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Seeger, F. H. Articles by Dimmeler, S. PubMed PubMed Citation Articles by Seeger, F. H. Articles by Dimmeler, S.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2009;29:1802.)
© 2009 American Heart Association, Inc.

Integrative Physiology/Experimental Medicine

CXCR4 Expression Determines Functional Activity of Bone Marrow–Derived Mononuclear Cells for Therapeutic Neovascularization in Acute Ischemia

Florian H. Seeger; Tina Rasper; Masamichi Koyanagi; Henrik Fox; Andreas M. Zeiher; Stefanie Dimmeler

From the Institute for Cardiovascular Regeneration (F.H.S., T.R., M.K., H.F.), Centre of Molecular Medicine (S.D.), and the Department of Cardiology, Internal Medicine III (F.H.S., H.F., A.M.Z.), Goethe University, Frankfurt (Main), Germany.

Correspondence to Stefanie Dimmeler, PhD, Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, University of Frankfurt, Haus 25, 4 Stock, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany. E-mail dimmeler{at}em.uni-frankfurt.de

Objective— Bone marrow–derived mononuclear cells (BMCs) improve the functional recovery after ischemia. However, BMCs comprise a heterogeneous mixture of cells, and it is not known which cell types are responsible for the induction of neovascularization after cell therapy. Because cell recruitment is critically dependent on the expression of the SDF-1-receptor CXCR4, we examined whether the expression of CXCR4 may identify a therapeutically active population of BMCs.

Methods and Results— Human CXCR4⁺ and CXCR4^– BMCs were sorted by magnetic beads. CXCR4⁺ BMCs showed a significantly higher invasion capacity under basal conditions and after SDF-1 stimulation. Hematopoietic or mesenchymal colony-forming capacity did not differ between CXCR4⁺ and CXCR4^– BMCs. Injection of CXCR4⁺ BMCs in mice after induction of hindlimb ischemia significantly improved the recovery of perfusion compared to injection of CXCR4^– BMCs. Likewise, capillary density was significantly increased in CXCR4⁺ BMC-treated mice. Because part of the beneficial effects of cell therapy were attributed to the release of paracrine effectors, we analyzed BMC supernatants for secreted factors. Importantly, supernatants of CXCR4⁺ BMCs were enriched in the proangiogenic cytokines HGF and PDGF-BB.

Conclusion— CXCR4⁺ BMCs exhibit an increased therapeutic potential for blood flow recovery after acute ischemia. Mechanistically, their higher migratory capacity and their increased release of paracrine factors may contribute to enhanced tissue repair.

BMCs comprise a heterogeneous mixture of cells, and it is not known which cell types are responsible for neovascularization. Here, we show that CXCR4⁺ BMCs exhibit an increased potential for blood-flow recovery after ischemia. Mechanistically, their higher migratory capacity and their increased release of paracrine factors may contribute to enhanced tissue repair.

Key Words: CXCR4 • BMC • cell therapy • neovascularization • functional activity • SDF-1 • HGF • PDGF-BB